iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-5
Go back to iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-5| (NASDAQ: DTIL) | Delayed: 7.01 +0.20 (2.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.81 | 52 Week High | $ | |||
| Open | $6.95 | 52 Week Low | $ | |||
| Day High | $7.20 | P/E | N/A | |||
| Day Low | $6.88 | EPS | $ | |||
| Volume | 101,849 | |||||
